After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more

256
37
Favorite

After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more

StreetInsider2021-08-24

After-Hours Stock Movers: Cara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

256

Report

Comment（37）

STKG
·2021-08-24
Good
Reply
2
Report
JPTL
·2021-08-24
?
Reply
4
Report
JoelLee
·2021-08-24
Reply and comment pls thx!
Reply
3
Report
Fold Replies
- SerenityMie:
  commented
  2021-08-24
  Reply
  Report
- JoelLee:
  Yyoyoyotogkfs
  2021-08-24
  Reply
  Report
- tungleh:
  Done
  2021-08-24
  Reply
  Report
th1s0ne
·2021-08-24
nice
Reply
5
Report
Fold Replies
- LennartM:
  wow
  2021-08-24
  Reply
  Report
GinOng
·2021-08-24
Good start for the week!
Reply
6
Report
Chanelyap
·2021-08-24
Like
Reply
10
Report
Fold Replies
- tungleh:
  Done
  2021-08-24
  Reply
  Report
小虎一飞冲天
·2021-08-24
Like pls. Thanks. ??
Reply
8
Report
Fold Replies
- tungleh:
  Done
  2021-08-24
  Reply
  Report
- CWL711:
  ok
  2021-08-24
  Reply
  Report
- chiusan:
  [like]
  2021-08-24
  Reply
  Report
7b66d4d9
·2021-08-24
Like n comment
Reply
9
Report
Fold Replies
- tungleh:
  Done
  2021-08-24
  Reply
  Report
- PSYCHO82:
  Done
  2021-08-24
  Reply
  Report
- Boo2bear:
  Done. Pls like
  2021-08-24
  Reply
  Report
View more 1 comments
CindyLoh
·2021-08-24
Good
Reply
3
Report
Fold Replies
- Ahhs:
  Good
  2021-08-24
  Reply
  Report
SanWangtikup
·2021-08-24
Good
Reply
1
Report
Huat1333
·2021-08-24
Wow....[財迷] [財迷] [財迷]
Reply
3
Report
再等等吧
·2021-08-24
[Observation] [Observation]
Reply
1
Report
K74
·2021-08-24
Okay
Reply
4
Report
hohok
·2021-08-24
Like pls
Reply
5
Report
Fold Replies
- 7b66d4d9:
  done
  2021-08-24
  Reply
  Report
- szueyann:
  ok
  2021-08-24
  Reply
  Report
- tungleh:
  Done
  2021-08-24
  Reply
  Report
Dreamchaser9
·2021-08-24
Ok
Reply
2
Report
KTTS
·2021-08-24
Good
Reply
1
Report
hpt
·2021-08-24
Good
Reply
2
Report
KongSH
·2021-08-24
Good day ahead and Make More Money for Everyone
Reply
2
Report
Fold Replies
- Ameliakoh:
  All the best
  2021-08-24
  Reply
  Report
tig2021
·2021-08-24
So shocked
Reply
3
Report
hoooooo
·2021-08-24
?
Reply
4
Report
Fold Replies
- hoooooo:
  ??
  2021-09-03
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2161577712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-24 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2161577712","market":"us","top_or_hot":-1,"title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CWH","symbol_name":"露营世界","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","article_id":"2161577712","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","pubTimestamp":1629762000,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CWH":"露营世界","TBPH":"Theravance Biopharma Inc.","MOS":"美国美盛","CARA":"Cara Therapeutics, Inc.","PANW":"Palo Alto Networks","MARK":"Remark控股","BXC":"布鲁林克斯","GEVO":"Gevo Inc.","FLXS":"弗莱克斯蒂尔工业"},"translate_title":"下班后股票市场：卡拉治疗公司、Theravance生物制药公司、Flexsteel公司等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BXC":0.9,"CARA":0.9,"CWH":0.9,"FLXS":0.9,"GEVO":0.9,"MARK":0.9,"MOS":0.9,"PANW":0.9,"TBPH":0.9},"content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":834153541,"gmtCreate":1629782695483,"gmtModify":1676530129772,"author":{"id":"3586131488444401","authorId":"3586131488444401","name":"STKG","avatar":"https://static.tigerbbs.com/730c2482b43ac1909a601868b378a6e4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586131488444401","authorIdStr":"3586131488444401"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834153541","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834117445,"gmtCreate":1629779507187,"gmtModify":1676530128884,"author":{"id":"3585350696038563","authorId":"3585350696038563","name":"JPTL","avatar":"https://static.tigerbbs.com/6f6dde4c2c1d83e8d80141b547948419","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585350696038563","authorIdStr":"3585350696038563"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834117445","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834131365,"gmtCreate":1629778564757,"gmtModify":1676530128499,"author":{"id":"3579882572140125","authorId":"3579882572140125","name":"JoelLee","avatar":"https://static.tigerbbs.com/e1f6c92b13d94cba61906c07dbbb2ab6","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":1,"crmLevelSwitch":1,"idStr":"3579882572140125","authorIdStr":"3579882572140125"},"htmlText":"Reply and comment pls thx!","listText":"Reply and comment pls thx!","text":"Reply and comment pls thx!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/834131365","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5633806,"gmtCreate":1629807814159,"gmtModify":1663232847935,"authorId":3581556843549192,"author":{"id":3581556843549192,"idStr":"3581556843549192","authorId":3581556843549192,"name":"SerenityMie","avatar":"https://static.tigerbbs.com/7beaf0f50fa9c54132bac0579576b755","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834131365,"type":1,"supId":0,"prevId":0,"content":"<u>commented</u>","text":"<u>commented</u>","html":"<u>commented</u>"},{"id":5629813,"gmtCreate":1629778576430,"gmtModify":1663232830529,"authorId":3579882572140125,"author":{"id":3579882572140125,"idStr":"3579882572140125","authorId":3579882572140125,"name":"JoelLee","avatar":"https://static.tigerbbs.com/e1f6c92b13d94cba61906c07dbbb2ab6","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":"80.53%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834131365,"type":1,"supId":0,"prevId":0,"content":"Yyoyoyotogkfs","text":"Yyoyoyotogkfs","html":"Yyoyoyotogkfs"},{"id":5629948,"gmtCreate":1629779206984,"gmtModify":1663232829568,"authorId":3581840130059040,"author":{"id":3581840130059040,"idStr":"3581840130059040","authorId":3581840130059040,"name":"tungleh","avatar":"https://static.itradeup.com/news/e7cd8f0c265e9dabe49dea7b97ffe6b9","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834131365,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":834108081,"gmtCreate":1629776624643,"gmtModify":1676530127945,"author":{"id":"3579772900389006","authorId":"3579772900389006","name":"th1s0ne","avatar":"https://static.tigerbbs.com/7eb0f4a742f6158068fdbcdd23f6740c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579772900389006","authorIdStr":"3579772900389006"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834108081","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5630414,"gmtCreate":1629782422517,"gmtModify":1663232833535,"authorId":3576017931077934,"author":{"id":3576017931077934,"idStr":"3576017931077934","authorId":3576017931077934,"name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834108081,"type":1,"supId":0,"prevId":0,"content":"wow","text":"wow","html":"wow"}],"langContent":"EN"},{"id":834370671,"gmtCreate":1629775225993,"gmtModify":1676530127666,"author":{"id":"3585489224255758","authorId":"3585489224255758","name":"GinOng","avatar":"https://static.tigerbbs.com/dbc4f4af938fe9cbc71173da2486f50b","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3585489224255758","authorIdStr":"3585489224255758"},"htmlText":"Good start for the week!","listText":"Good start for the week!","text":"Good start for the week!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834370671","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834355489,"gmtCreate":1629774153941,"gmtModify":1676530127285,"author":{"id":"3581317711527033","authorId":"3581317711527033","name":"Chanelyap","avatar":"https://static.tigerbbs.com/ead5a4e57e2f9f018e7802a33c0a28f5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581317711527033","authorIdStr":"3581317711527033"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834355489","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5629950,"gmtCreate":1629779214813,"gmtModify":1663232831548,"authorId":3581840130059040,"author":{"id":3581840130059040,"idStr":"3581840130059040","authorId":3581840130059040,"name":"tungleh","avatar":"https://static.itradeup.com/news/e7cd8f0c265e9dabe49dea7b97ffe6b9","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834355489,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":834329498,"gmtCreate":1629773317914,"gmtModify":1676530126874,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582098623642517","authorIdStr":"3582098623642517"},"htmlText":"Like pls. Thanks. ??","listText":"Like pls. Thanks. ??","text":"Like pls. Thanks. ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/834329498","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5629952,"gmtCreate":1629779223668,"gmtModify":1663232831551,"authorId":3581840130059040,"author":{"id":3581840130059040,"idStr":"3581840130059040","authorId":3581840130059040,"name":"tungleh","avatar":"https://static.itradeup.com/news/e7cd8f0c265e9dabe49dea7b97ffe6b9","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834329498,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"},{"id":5629137,"gmtCreate":1629773996304,"gmtModify":1663232825271,"authorId":3579262958727025,"author":{"id":3579262958727025,"idStr":"3579262958727025","authorId":3579262958727025,"name":"CWL711","avatar":"https://static.tigerbbs.com/982058e5cb33e9069dbb2ca28d3fc46e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834329498,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":5629595,"gmtCreate":1629776898102,"gmtModify":1631895880064,"authorId":4087951155083600,"author":{"id":4087951155083600,"idStr":"4087951155083600","authorId":4087951155083600,"name":"chiusan","avatar":"https://static.tigerbbs.com/e01f3d6c1717539be73315aef97eb361","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834329498,"type":1,"supId":0,"prevId":0,"content":"[like]","text":"[like]","html":"[like]"}],"langContent":"EN"},{"id":834312432,"gmtCreate":1629771652226,"gmtModify":1676530126150,"author":{"id":"4090291741868150","authorId":"4090291741868150","name":"7b66d4d9","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090291741868150","authorIdStr":"4090291741868150"},"htmlText":"Like n comment&nbsp;","listText":"Like n comment&nbsp;","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/834312432","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5629953,"gmtCreate":1629779229114,"gmtModify":1663232830934,"authorId":3581840130059040,"author":{"id":3581840130059040,"idStr":"3581840130059040","authorId":3581840130059040,"name":"tungleh","avatar":"https://static.itradeup.com/news/e7cd8f0c265e9dabe49dea7b97ffe6b9","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834312432,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"},{"id":5628958,"gmtCreate":1629772899668,"gmtModify":1663232826937,"authorId":3584840087767846,"author":{"id":3584840087767846,"idStr":"3584840087767846","authorId":3584840087767846,"name":"PSYCHO82","avatar":"https://static.tigerbbs.com/c7ab6b697c630c3b99e18227fdd119f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834312432,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5628825,"gmtCreate":1629772063397,"gmtModify":1663232825445,"authorId":3578969648963961,"author":{"id":3578969648963961,"idStr":"3578969648963961","authorId":3578969648963961,"name":"Boo2bear","avatar":"https://static.tigerbbs.com/209ae746c8124fe2d5f79aee784d2fcc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834312432,"type":1,"supId":0,"prevId":0,"content":"Done. Pls <u>like</u>","text":"Done. Pls <u>like</u>","html":"Done. Pls <u>like</u>"},{"id":5629014,"gmtCreate":1629773328674,"gmtModify":1663232825270,"authorId":3582098623642517,"author":{"id":3582098623642517,"idStr":"3582098623642517","authorId":3582098623642517,"name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834312432,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":834312091,"gmtCreate":1629771627313,"gmtModify":1676530126135,"author":{"id":"3581066751436729","authorId":"3581066751436729","name":"CindyLoh","avatar":"https://static.tigerbbs.com/0bcddadd449023bee1ba72042008a455","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581066751436729","authorIdStr":"3581066751436729"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834312091","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5629664,"gmtCreate":1629777413976,"gmtModify":1663232829131,"authorId":3577408537184208,"author":{"id":3577408537184208,"idStr":"3577408537184208","authorId":3577408537184208,"name":"Ahhs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834312091,"type":1,"supId":0,"prevId":0,"content":"<u>Good</u>","text":"<u>Good</u>","html":"<u>Good</u>"}],"langContent":"EN"},{"id":834332175,"gmtCreate":1629771135497,"gmtModify":1676530125858,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"4087452914358580","authorIdStr":"4087452914358580"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834332175","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834302683,"gmtCreate":1629770022042,"gmtModify":1676530125422,"author":{"id":"3559014783889591","authorId":"3559014783889591","name":"Huat1333","avatar":"https://community-static.tradeup.com/news/a4c138e1ce20043d7996468a91a225ac","vip":1,"hat":"https://static.tigerbbs.com/50a4c8d97279fa9f8f1fa9749a6bdff4","crmLevel":7,"crmLevelSwitch":1,"idStr":"3559014783889591","authorIdStr":"3559014783889591"},"htmlText":"Wow....[財迷]&nbsp;[財迷]&nbsp;[財迷]&nbsp;","listText":"Wow....[財迷]&nbsp;[財迷]&nbsp;[財迷]&nbsp;","text":"Wow....[財迷] [財迷] [財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834302683","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":834301548,"gmtCreate":1629769755584,"gmtModify":1676530125350,"author":{"id":"3570689023160998","authorId":"3570689023160998","name":"再等等吧","avatar":"https://static.tigerbbs.com/534b01f4d9f64217e12e115de2fef0e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570689023160998","authorIdStr":"3570689023160998"},"htmlText":"[Observation]&nbsp;[Observation]&nbsp;","listText":"[Observation]&nbsp;[Observation]&nbsp;","text":"[Observation] [Observation]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834301548","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834303613,"gmtCreate":1629769684632,"gmtModify":1676530125240,"author":{"id":"3574026189533561","authorId":"3574026189533561","name":"K74","avatar":"https://community-static.tradeup.com/news/0915c1dbb625a1fab842a01a98e9f31a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574026189533561","authorIdStr":"3574026189533561"},"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834303613","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834300722,"gmtCreate":1629769596866,"gmtModify":1676530125216,"author":{"id":"3581844295426037","authorId":"3581844295426037","name":"hohok","avatar":"https://static.tigerbbs.com/b9ae72338572431c58f911b40ae0f930","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581844295426037","authorIdStr":"3581844295426037"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/834300722","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5628737,"gmtCreate":1629771662652,"gmtModify":1663232824433,"authorId":4090291741868150,"author":{"id":4090291741868150,"idStr":"4090291741868150","authorId":4090291741868150,"name":"7b66d4d9","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834300722,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"},{"id":5628619,"gmtCreate":1629771122319,"gmtModify":1663232823826,"authorId":3573721781255613,"author":{"id":3573721781255613,"idStr":"3573721781255613","authorId":3573721781255613,"name":"szueyann","avatar":"https://static.tigerbbs.com/cba9c6b1e785a9cf7301a7e6a2ff2354","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834300722,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":5629955,"gmtCreate":1629779235637,"gmtModify":1635143928637,"authorId":3581840130059040,"author":{"id":3581840130059040,"idStr":"3581840130059040","authorId":3581840130059040,"name":"tungleh","avatar":"https://static.itradeup.com/news/e7cd8f0c265e9dabe49dea7b97ffe6b9","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834300722,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":834946954,"gmtCreate":1629768864078,"gmtModify":1676530124865,"author":{"id":"3581782846197879","authorId":"3581782846197879","name":"Dreamchaser9","avatar":"https://static.tigerbbs.com/f4f8f000953179179078bdd5e6f748b6","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581782846197879","authorIdStr":"3581782846197879"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834946954","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834948954,"gmtCreate":1629768808178,"gmtModify":1676530124865,"author":{"id":"4087885218846480","authorId":"4087885218846480","name":"KTTS","avatar":"https://static.tigerbbs.com/47ced277f059e21b882c591a54fd447d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087885218846480","authorIdStr":"4087885218846480"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834948954","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834949746,"gmtCreate":1629768643785,"gmtModify":1676530124795,"author":{"id":"3579759306103275","authorId":"3579759306103275","name":"hpt","avatar":"https://static.tigerbbs.com/986ef7c951112f7be64cfd5d6c1672c5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3579759306103275","authorIdStr":"3579759306103275"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834949746","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834928271,"gmtCreate":1629767847493,"gmtModify":1676530124348,"author":{"id":"4091169623174150","authorId":"4091169623174150","name":"KongSH","avatar":"https://static.tigerbbs.com/4db5a338d9f077992726659f508a7685","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091169623174150","authorIdStr":"4091169623174150"},"htmlText":"Good day ahead and Make More Money for Everyone&nbsp;","listText":"Good day ahead and Make More Money for Everyone&nbsp;","text":"Good day ahead and Make More Money for Everyone","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834928271","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5627893,"gmtCreate":1629768091492,"gmtModify":1663232820636,"authorId":3574754838536636,"author":{"id":3574754838536636,"idStr":"3574754838536636","authorId":3574754838536636,"name":"Ameliakoh","avatar":"https://static.tigerbbs.com/4a747ab791603fb0a649736b10ec7454","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834928271,"type":1,"supId":0,"prevId":0,"content":"All the best","text":"All the best","html":"All the best"}],"langContent":"EN"},{"id":834923702,"gmtCreate":1629767788706,"gmtModify":1676530124300,"author":{"id":"3587008457873110","authorId":"3587008457873110","name":"tig2021","avatar":"https://static.tigerbbs.com/86558e2c1be0fae967630b306994ef5a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3587008457873110","authorIdStr":"3587008457873110"},"htmlText":"So shocked","listText":"So shocked","text":"So shocked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/834923702","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834965744,"gmtCreate":1629767587988,"gmtModify":1676530124182,"author":{"id":"3573647787670033","authorId":"3573647787670033","name":"hoooooo","avatar":"https://static.tigerbbs.com/39fb086e59b85d332e38211a7fc755af","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573647787670033","authorIdStr":"3573647787670033"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/834965744","repostId":2161577712,"repostType":4,"repost":{"id":"2161577712","pubTimestamp":1629762000,"share":"https://ttm.financial/m/news/2161577712?lang=&edition=fundamental","pubTime":"2021-08-24 07:40","market":"us","language":"en","title":"After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2161577712","media":"StreetInsider","summary":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today ann","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/CARA\">Cara Therapeutics</a> 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .</p>\n<p><a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma</a> 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.</p>\n<p><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a> (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.</p>\n<p><a href=\"https://laohu8.com/S/FLXS\">Flexsteel</a> 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.</p>\n<p><a href=\"https://laohu8.com/S/BXC\">BlueLinx</a> 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.</p>\n<p><a href=\"https://laohu8.com/S/CWH\">Camping World Holdings Inc.</a> 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.</p>\n<p><a href=\"https://laohu8.com/S/GEVO\">Gevo</a> 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.</p>\n<p><a href=\"https://laohu8.com/S/MARK\">Remark Media</a> 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.</p>\n<p><a href=\"https://laohu8.com/S/MOS\">Mosaic</a> 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Mover: Cara Therapeutics,Theravance Biopharma,Flexsteel and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-24 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18852924><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18852924\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FLXS":"弗莱克斯蒂尔工业","CWH":"露营世界","CARA":"Cara Therapeutics, Inc.","MOS":"美国美盛","PANW":"Palo Alto Networks","MARK":"Remark控股","GEVO":"Gevo Inc.","TBPH":"Theravance Biopharma Inc.","BXC":"布鲁林克斯"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18852924","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161577712","content_text":"After-Hours Stock Movers:\nCara Therapeutics 27% HIGHER; Cara Therapeutics and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis .\nTheravance Biopharma 22% LOWER; Announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. The study did not meet its primary endpoint of change in the total Mayo score or the key secondary endpoint of clinical remission at week 8, relative to placebo. There was a small dose-dependent increase in clinical response measured by the adapted Mayo score, which was driven by a reduction in rectal bleeding.\nPalo Alto Networks (NYSE: PANW) 10.1% HIGHER; reported Q4 EPS of $1.60, $0.16 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.17 billion. Palo Alto Networks sees Q1 2022 EPS of $1.55-$1.58, versus the consensus of $1.60. Palo Alto Networks sees Q1 2022 revenue of $1.19-1.21 billion, versus the consensus of $1.15 billion. Palo Alto Networks sees FY2022 EPS of $7.15-$7.25, versus the consensus of $7.09. Palo Alto Networks sees FY2022 revenue of $5.275-5.325 billion, versus the consensus of $4.98 billion.\nFlexsteel 6.8% HIGHER; reported Q4 EPS of $0.61. Revenue for the quarter came in at $136.2 million.\nBlueLinx 6.6% HIGHER; announced today the termination of its at-the-market equity offering program (the ATM Offering) with Jefferies LLC (Jefferies) as sales agent. Also announced that its Board of Directors authorized a new share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock in the open market.\nCamping World Holdings Inc. 5.3% HIGHER; declared a quarterly dividend of $0.50 per share, or $2 annualized. This is a 100% increase from the prior dividend of $0.25.\nGevo 4.5% HIGHER; Stifel initiates coverage with a Buy rating and a price target of $10.00.\nRemark Media 2.6% LOWER; reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.78 million.\nMosaic 1% HIGHER; The Board of Directors has approved a new $1 billion share repurchase authorization, which replaces the previous authorization that had $700 million of the original $1.5 billion remaining.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5734591,"gmtCreate":1630623349360,"gmtModify":1663233301946,"authorId":3573647787670033,"author":{"id":3573647787670033,"idStr":"3573647787670033","authorId":3573647787670033,"name":"hoooooo","avatar":"https://static.tigerbbs.com/39fb086e59b85d332e38211a7fc755af","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":834965744,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":256,"commentSize":37,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}